Fulcrum Therapeutics (NASDAQ:FULC) shares are trading sharply lower in after-hours trading on Monday.
FULC shares plunged 49.69% to $3.23 in after-hours trading after the company announced it was discontinuing pociredir, its lead experimental drug for sickle cell disease, and launched a strategic review process.
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for rare hematological disorders.
Program Discontinuation Announcement
The company said it is discontinuing development of pociredir for sickle cell disease following feedback from the Food and Drug Administration.
